Document is current

Article History

Received: 16 March 2021

Revised: 21 June 2021

Accepted: 22 June 2021

First Online: 15 July 2021

Declarations

:

: This is a monocentric retrospective study; all data of participants are retrieved from the electronic records. This study was conducted in accordance with the tenets of the Declaration of Helsinki. All study-related data acquisitions were approved by a French Institutional Review Board (IRB) (IRB 00008855).

: Abir Zureik, Ali Erginay, and Vanessa Juddoo have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.Aude Couturier is a board member of Allergan (Ireland), Bayer HealthCare (Germany), and Novartis Pharma (Switzerland), and has received travel grants from Allergan (Ireland) and Bayer HealthCare (Germany).Ramin Tadayoni is a board member of several companies (Alcon, Switzerland; Novartis, Switzerland; Roche, Switzerland; Allergan, USA; Bausch and Lomb, USA; Genentech, USA; Pfizer, USA; Alimera, USA; Bayer, Germany; FCI-Zeiss, France; Thrombogenics, Belgium) and consultant (Allergan, USA; DORC, Netherlands; Alcon, Switzerland; Novartis, Switzerland; Bausch and Lomb, USA; FCI-Zeiss, France; Thrombogenics, Belgium), has received lecture fees (Alcon, USA; Bausch and Lomb, USA; Novartis, Switzerland; Allergan, USA; Bayer, Germany; Alimera, USA), educational presentation fees (Bausch and Lomb, USA; Novartis, Switzerland; Zeiss, Germany; Sony, Japan; Alcon, Switzerland; Allergan, USA), and meeting expenses (Novartis, Switzerland; Alcon, Switzerland; Allergan, USA; Bausch and Lomb, USA; Pfizer, USA; Bayer, Germany; DORC, Netherlands; Alimera, USA).Pascale Massin is a board member of Allergan (Ireland), Bayer HealthCare (Germany), Novartis Pharma (Switzerland), and Horus (France).Jean-Baptiste Julla reports personal fees and non-financial support from Novo Nordisk and Sanofi, and non-financial support from MSD.Tiphaine Vidal-Trecan reports personal fees and non-financial support from Novo Nordisk, MSD, and Roche.Jean-François Gautier reports personal fees and non-financial support from Eli Lilly, personal fees and non-financial support from Novo Nordisk, personal fees and nonfinancial support from Gilead, and personal fees and non-financial support from AstraZeneca.Jean-Pierre Riveline is an advisory panel member of Sanofi, MSD, Eli Lilly, Novo Nordisk, Abbott, and Medtronic; and has received research funding from and provided research support to Abbott, Air liquide, Sanofi, and Novo Nordisk.